米国カリフォルニア州マウンテンビュー–(BUSINESS WIRE)–（ビジネスワイヤ）―神経系疾患を対象に再生細胞薬の開発・製造を手掛ける当社グループ（サンバイオ株式会社及びその子会社であるSanBio, Inc.） は、今般、American Heart Association（米国心臓協会）が発刊している専門誌Strokeに、論文「脳梗塞患者を対象とした、一過性に遺伝子導入した骨髄由来間葉系幹細胞を用いたフェーズ1/2a試験結果（Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study）」を発表しましたのでお知らせします。本論文では、脳梗塞により運動障害をきたした慢性期の患者を対象に再生細胞薬SB623（以下、「本剤」）を投与した2年間の臨床試験で得られた、本剤投与後12ヵ月までの試験データを発表しています。本論文では、脳梗塞発症後6ヵ月から5年が経過した慢性期の運動障害を持つ患者に対する、本剤投与の忍
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph….
OXFORD, England & SAN FRANCISCO–(BUSINESS WIRE)–#3d–Fuel3D, a leading 3D capture and imaging innovator, today announced the delivery of its first enterprise 3D scanning project – a new foot-scanning system for the orthotics industry.
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and …
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference
PARIS–(BUSINESS WIRE)–Pixium Vision (Paris:PIX) (FR0011950641 – PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS® II bionic vision system. This system being evaluated includes
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today top-line results from the Phase 2b/3 clinical trial (S.E.A.T.T.L.E. study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat). The study enrolled 508 patients with geographic atrophy (GA) secondary to age-
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Glass Lens Market 2016-2020” report to their offering. The global glass lens market to grow at a CAGR of 3.55% during the period 2016-2020. Global Glass Lens Market…
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration that has developed and is currently marketing the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced today that Todd Cooper, President and CEO, is scheduled to present at the Jefferies 2016 Global Healthcare Conference on Tuesday, June 7, 2016 at 10:00 a.m. ET. The Conference is being held from June 7 to 10, 2016 in New York, NY
WATERTOWN, Mass.–(BUSINESS WIRE)–Selecta Biosciences, Inc. has obtained an exclusive license to Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear for a rare genetic disease with additional options.
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ocular Disorders: Rising Therapeutics, Technologies, and Devices – Overview ” report to their offering. Available to Report is Ocular Disorders: Rising Therapeutics, Techn…
HOUSTON–(BUSINESS WIRE)–#acne–ZOCUZAP, a revolutionary new okra-based product manages acne and improves skin tone and texture. Just one wipe once a day is all it takes to see dramatic improvements in facial appearance.
SEATTLE–(BUSINESS WIRE)–Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Optical Coherence Tomography (OCT) – Medical Devices Pipeline Assessment, 2016” drug pipelines to their offering. The report provides comprehensive information on the pipe…
PLEASANTON, Calif.–(BUSINESS WIRE)–CooperVision Unveils 2015 Best Practices Honorees. Inaugural Class of 10 Honorees Will Be Broadly Recognized for their Success in Optometry.
米国カリフォルニア州マウンテンビュー–(BUSINESS WIRE)–（ビジネスワイヤ） — 再生細胞薬の開発・製造を手掛ける当社グループ（サンバイオ株式会社およびその子会社であるSanBio Inc.）は、この度、独自に開発を進めている再生細胞薬SB623（以下、「本剤」）について、網膜変性疾患を対象とした特許を米国特許商標局（USPTO）から取得しましたのでお知らせします。当社は、中枢神経系において神経再生を促進する再生細胞薬SB623を開発しており、網膜変性疾患を含む神経細胞が関与する様々な疾患に対する治療薬の提供を目指しています。 2016年5月3日に取得が完了した特許（米国特許番号No. 9,326,999 B2）は、再生細胞薬SB623の用途特許で、光受容体機能の向上を促進することで網膜変性疾患を治療するというものです。網膜色素変性や加齢黄斑変性をはじめとする網膜変性疾患は、視細胞や網膜色素上皮が変性することで視力が減弱します。網膜変性疾患の中でも網膜色素変性症や、萎縮型加齢黄斑変性は有効な治療法がなく、また最終的には失明に至る場合もあるため、有効な治療法が求められ
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Proliferative Diabetic Retinopathy (PDR) – Pipeline Review, H1 2016” report to their offering. This report provides comprehensive information on the therapeutic developmen…
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Bacterial Conjunctivitis – Pipeline Review, H1 2016” report to their offering. The report provides comprehensive information on the therapeutics under development for Bact…
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek today reported financial results and operational highlights for the quarter ended March 31, 2016.
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting infl…